Osteoglycin在口腔鳞状细胞癌中的表达及临床意义

doi:10.13701/j.cnki.kqyxyj.2026.03.011

摘要/Abstract

摘要： 目的:探讨骨诱导因子(osteoglycin,OGN)在口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)组织中的表达情况,并分析其与患者临床病理特征及生存预后的相关性。方法:选取80例OSCC患者石蜡组织标本。利用免疫组织化学技术检测OGN蛋白表达水平,评估其表达与患者临床病理特征的关系。采用Kaplan-Meier法评估OGN表达与患者预后的关系。应用cBioPortal数据库分析OGN与蛋白激酶B(protein kinase B,AKT1)等基因表达的相关性。结果:OSCC中OGN表达显著高于癌旁组织,主要定位于肿瘤细胞,且在浸润前沿的表达高于肿瘤中心。OGN高表达与更晚的TNM分期、更高的T分期和淋巴结转移率相关(P<0.05),伴随较高的Ki-67阳性率,患者总生存率降低(P<0.05)。OGN与AKT1、哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)、波形蛋白(vimentin,VIM)等上皮-间充质转化(epithelial-mesenchymal transition,EMT)分子表达呈正相关。结论:OGN在OSCC组织中表达上调,其高表达提示患者预后不良。

关键词: 口腔鳞状细胞癌, 骨诱导因子, 临床病理特征, 预后

Abstract: Objective: To investigate the expression of osteoglycin (OGN) in oral squamous cell carcinoma (OSCC) tissues and analyze its correlation with patients' clinical pathological characteristics and survival prognosis. Methods: Eighty cases of OSCC paraffin tissue specimens were selected. Immunohistochemistry was used to detect OGN protein expression levels and evaluate the relationship between its expression and clinical pathological characteristics of patients. Kaplan-Meier method was used to evaluate the relationship between OGN expression and prognosis of patients. The correlation between OGN and protein kinase B (AKT1) et al. gene expression was analyzed by cBioPortal database. Results: OGN expression was significantly higher in OSCC than in adjacent normal tissue, mainly localized in tumor cells, and was higher in invasive tumor front than in the tumor center. High OGN expression was associated with later TNM stage, higher T stage, and lymph node metastasis rate (P<0.05), accompanied by a higher Ki-67 positivity rate, and decreased overall survival rate in patients (P<0.05). OGN was positively correlated with epithelial-mesenchymal transition molecules, such as AKT1, mammalian target of rapamycin (mTOR), and vimentin (VIM). Conclusion: OGN is overexpressed in OSCC, and its high expression indicates poor prognosis of patients.

Key words: oral squamous cell carcinoma, osteoglycin, clinical pathological features, prognosis

贺一家, 张馨文, 王泽正, 李子慧, 丁亮, 王志勇. Osteoglycin在口腔鳞状细胞癌中的表达及临床意义[J]. 口腔医学研究, 2026, 42(3): 235-241.

HE Yijia, ZHANG Xinwen, WANG Zezheng, LI Zihui, DING Liang, WANG Zhiyong. Expression and Clinical Significance of Osteoglycin in Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2026, 42(3): 235-241.

参考文献

[1] Fan T, Wang X, Zhang S, et al. NUPR1 promotes the proliferation and metastasis of oral squamous cell carcinoma cells by activating TFE3-dependent autophagy[J]. Signal Transduct Target Ther, 2022, 7(1):130.
[2] Perez-Pacheco CG, Gonzalez-Maldonado LA, Furgal A, et al. Nerve types and classification of neurons innervating oral cancer[J]. Clin Cancer Res, 2025, 31(13):2741-2755.
[3] Dong L, Xue L, Cheng W, et al. Comprehensive survival analysis of oral squamous cell carcinoma patients undergoing initial radical surgery[J]. BMC Oral Health, 2024, 24(1):919.
[4] 韩冰,张伟,俞辉明.术前血红蛋白、白蛋白和球蛋白比值在口腔鳞癌患者预后中的预测价值[J].口腔生物医学, 2025, 16(3):150-154+164.
[5] Radaic A, Kamarajan P, Cho A, et al. Biological biomarkers of oral cancer[J]. Periodontol 2000, 2024, 96(1):250-280.
[6] Tan Y, Wang Z, Xu M, et al. Oral squamous cell carcinomas: state of the field and emerging directions[J]. Int J Oral Sci, 2023, 15(1):44.
[7] Jagadeesan D, Sathasivam KV, Fuloria NK, et al. Comprehensive insights into oral squamous cell carcinoma: Diagnosis, pathogenesis, and therapeutic advances[J]. Pathol Res Pract, 2024, 261:155489.
[8] 章锐,杜秋丽,阮剑,等.Osteoglycin通过上调雌激素受体表达抑制Luminal型乳腺癌细胞增殖[J].中国普外基础与临床杂志,2021,28(12):1580-1586.
[9] Theocharis AD, Manou D, Karamanos NK. The extracellular matrix as a multitasking player in disease[J]. FEBS J, 2019, 286(15):2830-2869.
[10] Nikitovic D, Aggelidakis J, Young MF, et al. The biology of small leucine-rich proteoglycans in bone pathophysiology[J]. J Biol Chem, 2012, 287(41):33926-33933.
[11] Tanaka K, Matsumoto E, Higashimaki Y, et al. Role of osteoglycin in the linkage between muscle and bone[J]. J Biol Chem, 2012, 287(15):11616-11628.
[12] Tasheva ES, Koester A, Paulsen AQ, et al. Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities[J]. Mol Vis, 2002, 8:407-415.
[13] Shanahan CM, Cary NR, Osbourn JK, et al. Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques[J]. Arterioscler Thromb Vasc Biol, 1997, 17(11):2437-2447.
[14] Yang M, Hu H, Wu S, et al. EIF4A3-regulated circ_0087429 can reverse EMT and inhibit the progression of cervical cancer via miR-5003-3p-dependent upregulation of OGN expression[J]. J Exp Clin Cancer Res, 2022, 41(1):165.
[15] Kameda T, Sugihara T, Obinata D, et al. Androgen receptor and osteoglycin gene expression predicting prognosis of metastatic prostate cancer[J]. Sci Rep, 2024, 14(1):30654.
[16] Xu S, Chen C, Liu H, et al. Osteoglycin inhibits the progression of lung adenocarcinoma by modulating ICAM1-mediated cell adhesion via the PI3K/AKT pathway[J]. Mol Carcinog, 2025, 64(9):1564-1579.
[17] Qin W, Zhang J, Rong R, et al. Osteoglycin (OGN) promotes tumorigenesis of pancreatic cancer cell via targeting ID4[J]. Tissue Cell, 2022, 78:101867.
[18] Chen H, Yang L, Sun W. Elevated OGN expression correlates with the EMT signature and poor prognosis in ovarian carcinoma[J]. Int J Clin Exp Pathol, 2019, 12(2):584-589.
[19] Wang J, Lv P. Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells[J]. Bioengineered, 2021, 12(1):755-762.
[20] Zhu N, Ding L, Fu Y, et al. Tumor-infiltrating lymphocyte-derived MLL2 independently predicts disease-free survival for patients with early-stage oral squamous cell carcinoma[J]. J Oral Pathol Med, 2020, 49(2):126-136.
[21] He Y, Liu L, Dong Y, et al. Lipid droplets-related Perilipin-3: potential immune checkpoint and oncogene in oral squamous cell carcinoma[J]. Cancer Immunol Immunother, 2024, 73(5):78.
[22] Nulali J, Zhan M, Zhang K, et al. Osteoglycin: An ECM factor regulating fibrosis and tumorigenesis[J]. Biomolecules, 2022, 12(11):1674.
[23] Moreno-Ulloa A, Zárate-Córdova VL, Ramírez-Sánchez I, et al. Evaluation of a proteomics-guided protein signature for breast cancer detection in breast tissue[J]. J Proteome Res, 2024, 23(11):4907-4923.
[24] Wassermann-Dozorets R, Rubinstein M. C/EBPβ LIP augments cell death by inducing osteoglycin[J]. Cell Death Dis, 2017, 8(4):e2733.
[25] Wang Y, Ma Y, Lü B, et al. Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study[J]. Exp Biol Med (Maywood), 2007, 232(9):1152-1159.
[26] Xu T, Zhang R, Dong M, et al. Osteoglycin (OGN) inhibits cell proliferation and invasiveness in breast cancer via PI3K/Akt/mTOR signaling pathway[J]. Onco Targets Ther, 2019, 12:10639-10650.
[27] Hu X, Li YQ, Li QG, et al. Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway[J]. J Exp Clin Cancer Res, 2018, 37(1):41.
[28] Ren N, Liang B, Li Y. Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets[J]. Biosci Rep, 2020, 40(10):BSR20200980.
[29] Yu X, Yu B, Fang W, et al. Identification hub genes of consensus molecular subtype correlation with immune infiltration and predict prognosis in gastric cancer[J]. Discov Oncol, 2021, 12(1):41.
[30] 邹岩,姜桂春,李辉,等.骨甘蛋白在胃癌细胞干性维持及对化疗敏感性中的作用[J].消化肿瘤杂志(电子版),2022,14(4):431-436.
[31] Huang J, Zhang L, Wan D, et al. Extracellular matrix and its therapeutic potential for cancer treatment[J]. Signal Transduct Target Ther, 2021, 6(1):153.
[32] Guntur AR, Rosen CJ, Naski MC. N-cadherin adherens junctions mediate osteogenesis through PI3K signaling[J]. Bone, 2012, 50(1):54-62.
[33] Zuo C, Li X, Huang J, et al. Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling[J]. Cardiovasc Res, 2018, 114(5):703-712.
[34] Fang Y, Chang Z, Xu Z, et al. Osteoglycin silencing exerts inhibitory effects on myocardial fibrosis and epithelial/endothelial-mesenchymal transformation in a mouse model of myocarditis[J]. Biofactors, 2020, 46(6):1018-1030.
[35] Tengryd C, Nielsen SH, Cavalera M, et al. The proteoglycan mimecan is associated with carotid plaque vulnerability and increased risk of future cardiovascular death[J]. Atherosclerosis, 2020, 313:88-95.
[36] Mei Y, Du Z, Hu C, et al. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling[J]. Cell Commun Signal, 2017, 15(1):34.